A Randomized Controlled Trial Comparing 21 Days of Continuous Subcutaneous Insulin Infusion (CSII) Using Hepatic Directed Vesicle (HDV) Insulin to Standard CSII in Type 1 Diabetes Mellitus
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2018
At a glance
- Drugs Insulin lispro (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Diasome Pharmaceuticals
- 30 Jan 2018 Planned End Date changed from 1 Jan 2018 to 15 Feb 2018.
- 30 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 23 May 2017 New trial record